No Data
Luyan Pharmaceutical: Report for the first quarter of 2025
Luyan Pharmaceutical: 2024 Annual Report Summary
Luyan Pharmaceutical: 2024 Annual Report
Luyan Pharma (002788.SZ): Net income for the year 2024 is 0.346 billion yuan, with a proposal to distribute 3.5 yuan per share.
On April 21, Gelonghui reported that Luyan Pharma (002788.SZ) published its annual report for 2024. In 2024, the company achieved total operating revenue of 20.471 billion yuan, an increase of 3.15% compared to the same period last year; net income attributable to shareholders of the listed company was 0.346 billion yuan, a decrease of 4.92% compared to the same period last year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.347 billion yuan, an increase of 0.33% compared to the same period last year; basic EPS was 0.89 yuan; it is proposed to distribute a cash dividend of 3.50 yuan (including tax) for every 10 shares to all shareholders.
Luyan Pharma (002788.SZ): The Bozhou Modern Traditional Chinese Medicine Industrial Park project is currently still in the process of decoration and equipment installation and commissioning.
On December 23, Luyan Pharma (002788.SZ) stated on the investor interaction platform that, 1. The company will continue to operate in a standardized manner, continuously enhancing its core competitiveness, improving performance, and rewarding investors. 2. The Bozhou Modern Traditional Chinese Medicine Industry Park project is currently still in the process of decoration and equipment installation and debugging, and the company will strive to put the project into production as soon as possible. 3. The company continues to strengthen innovation leadership, focusing on implementation, cultivating and incubating new technologies and new models with innovative potential. The AI-assisted diagnostic products independently developed by the company in the fields of electrocardiogram, fetal heart, and others have obtained registration certification as medical instruments.
Luyan Pharma (002788.SZ): Actively exploring and developing AI and Big Data applications in the medical health service field.
On December 19, Gelonghui reported that Luyan Pharma (002788.SZ) recently stated during its reception of institutional investor research that the company is building a new development pattern of "one platform + two grasping hands". Using Luyan's healthy living business as a platform, it continues to create value and aims to strengthen, expand, and optimize its operations. The two grasping hands focus on the modernization of Traditional Chinese Medicine and new technology industries, creating the Luyan healthy living ecosystem and establishing a new development highland for Luyan. Efforts are being made to advance the construction of the modern Traditional Chinese Medicine production project in Bozhou, which began construction in February 2022. The first phase was capped in March this year, and currently, it is undergoing renovations and equipment installation.
Earnings Working Against Luyan Pharma Co.,Ltd.'s (SZSE:002788) Share Price Following 29% Dive
